Recursion Pharmaceuticals Inc. acquires full rights to REV102, a potential oral therapy for rare bone disorder hypophosphatasia, through a $25 million deal with Rallybio Corporation. REV102, an ENPP1 inhibitor, is in preclinical development for HPP patients. Rallybio will receive royalties on net sales and additional payments if REV102 is sold to a third party.

Recursion Pharmaceuticals is a clinical-stage biotech company specializing in drug discovery, while Rallybio Corporation focuses on developing therapies for severe and rare diseases. RXRX and RLYB are publicly traded on the NASDAQ. Rallybio will receive low single-digit royalties on all future net sales of REV102 by Recursion.

RXRX is considered one of the best small cap AI stocks by analysts. The collaboration between Rallybio and Recursion led to the development of REV102, which entered IND-enabling studies in early 2025. Investors seeking undervalued AI stocks with potential upside should consider other options, according to analysts.

Read more at Yahoo Finance: Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia